ClinicalTrials.gg
Active, not recruitingNCT04542824EPCORE™ NHL-3Updated Nov 4, 2026

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

A Phase 1/2 interventional study of Epcoritamab (monotherapy) and Epcoritamab in Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma and Primary Mediastinal Large B Cell Lymphoma, sponsored by Genmab. Active, not recruiting at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
9th of 24
78 · median 41
Started
2020
with 1 other
Phase 1/2
3 of 24
1 open now
Primary completion
2027-09
later than 5 of 22 live
Registered
1st of 24
by date
Lead sponsor
8 of 24
Genmab

Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one is the 9th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 1/2, reaches primary completion later than 5 of the 22 other live ones, and was the 1st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About epcoritamab

epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior standard of care (SOC). The trial consists of two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2).

The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese participants with relapsed, progressive or refractory B-cell lymphoma and Japanese participants with B-cell lymphomas that have achieved PR or CR.

In the expansion part, additional participants will be treated with epcoritamab, at the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab.

Part 2 of the trial will be initiated once the RP2D has been determined in Part 1. In Part 2, epcoritamab is investigated as a monotherapy and in combination with other SOC agents.

Read the detailed description

All participants in the trial will receive epcoritamab, as monotherapy or in combination with SOC. The following regimens will be investigated in Part 2:

Arm 1: epcoritamab monotherapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

Arm 2: epcoritamab + rituximab and lenalidomide (R2) in participants with R/R FL

Arm 3: epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in participants with previously untreated DLBCL with high risk features

Arm 4: epcoritamab + gemcitabine and oxaliplatin (GemOx) in participants with R/R DLBCL who either failed prior autologous hematopoietic stem cell transplantation (ASCT), or are ineligible for autologous HSCT.

Arm 5: epcoritamab maintenance in participants with FL who achieve a CR or a PR following first line (1L)/second line (2L) SOC treatment

03

Conditions studied

  • Diffuse Large B Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Primary Mediastinal Large B Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Must be at least 20 years of age, inclusive
  • Japanese participants
  • CD20 positivity at representative tumor
  1. Part 1:

    • Diffuse large B-cell lymphoma (de novo or histologically transformed)
    • High-grade B-cell lymphoma
    • Primary mediastinal large B-cell lymphoma
    • Follicular lymphoma
    • Marginal zone lymphoma (nodal, extranodal of mucosa-associated lymphoid tissue, or splenic)
    • Small lymphocytic lymphoma
  2. Part 2 :

    Arm 1:

    • Diffuse large B-cell lymphoma (de novo or histologically transformed)
    • Follicular lymphoma grade 1-3A
    • disease and previously treated with at least 2 lines of systemic antineoplastic therapy including at least 1 anti-CD20 monoclonal antibody (mAb)-containing therapy.
    • by computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET)-CT scan

    Arm 2:

    • R/R FL grade 1, 2 or 3a, stage II, III, or IV, without evidence of transformation.
    • Previously treated with at least 1 prior anti-neoplastic agent, including anti-CD20 antibody
    • Must have a need for treatment initiation based on symptoms and/or disease burden (Groupe d'Etude des Lymphomes Folliculaires [GELF] criteria)
    • Eligible to receive R2 per investigator determination

    Arm 3:

    • One of following confirmed histologies (de novo or histologically transformed from FL or nodal marginal zone lymphoma) :

      o DLBCL, not otherwise specified (NOS)

      • "Double-hit" or "triple-hit" DLBCL
      • FL Grade 3B.
      • T-cell/histiocyte rich large B-cell lymphoma (LBCL)
    • International Prognostic Index (IPI) score ≥3
    • No prior therapy for DLBCL or FL grade 3B (G3B) other than nodal biopsy, , or palliative radiotherapy.
    • Eligible to receive R-CHOP per investigator determination

    Arm 4:

    • One of following confirmed histologies (de novo or histologically transformed from FL or nodal marginal zone lymphoma) including:

      o DLBCL, NOS.

      o "Double-hit" or "triple-hit" DLBCL

      • FL Grade 3B.
      • T-cell/histiocyte rich LBCL
    • Relapsed or refractory to at least one prior therapy including at least one prior anti-CD20 antibody.
    • Either failed prior hematopoietic stem cell transplantation (ASCT), or ineligible for autologous hematopoietic stem-cell transplantation (HSCT)
    • Eligible to receive GemOx per investigator determination

    Arm 5:

    • History of confirmed CD20+ FL Grade 1-3a without evidence of transformation.
    • In CR or PR per Lugano criteria following or second-line treatment with SOC regimen, including anti-CD20 antibody, and last dose of SOC within 6 months prior to enrollment

    Main Exclusion Criteria:

    • Primary central nervous system (CNS) lymphoma or CNS involvement by lymphoma at screening
    • Participants not eligible for high dose therapy with autologous hematopoietic stem cell transplantation due to personal choice, social issues, or similar
    • Known cardiac disease
    • Chronic ongoing infectious diseases requiring treatment (excluding prophylactic treatment)

    Exclusion criteria for Part 2, Arms 2 through 5:

    Arm 2:

    • FL Grade 3b
    • Histologic evidence of transformation to an aggressive lymphoma
    • to rituximab or lenalidomide
    • Unwilling or unable to take aspirin prophylaxis or prophylactic anticoagulant as clinically indicated

    Arm 3:

    • Contraindication to any of the individual drugs of the R-CHOP regimen

    Arm 4:

    • Contraindication to any of the individual drugs of the GemOx regimen

    Arm 5:

    • FL Grade 3b
    • Histologic evidence of transformation to an aggressive lymphoma
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Arm 1: Epcoritamab

    In participants with DLBCL/FL.

    Biological: Epcoritamab (monotherapy)

  • Experimental
    Arm 2: Epcoritamab + Rituximab + Lenalidomide

    In participants with R/R FL

    Biological: Epcoritamab · Drug: Rituximab and lenalidomide

  • Experimental
    Arm 3: Epcoritamab + Rituximab + Cyclophosphamide+ Doxorubicin+ Vincristine + Prednisone

    In participants with previously untreated DLBCL

    Biological: Epcoritamab · Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

  • Experimental
    Arm 4: Epcoritamab + Gemcitabine + Oxaliplatin

    In participants with relapsed/refractory DLBCL

    Biological: Epcoritamab · Drug: Gemcitabine and oxaliplatin

  • Experimental
    Arm 5: Epcoritamab Maintenance

    In participants with FL in CR or in PR following 1L or 2L SOC treatment

    Biological: Epcoritamab (maintenance)

Interventions

  • Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • BiologicalEpcoritamab

    Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • DrugRituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

    21-day cycles

    Also known as: R-CHOP

  • DrugGemcitabine and oxaliplatin

    Drug pages: Gemcitabine · Oxaliplatin

    28-day cycles

    Also known as: GemOx

  • 28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • DrugRituximab and lenalidomide

    Drug pages: Rituximab · Lenalidomide

    28-day cycles.

    Also known as: R2

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years

  2. Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)

    Time frame: DLTs are assessed during the first cycle (28 days) in each cohort

  3. Part 2, Arm 1: Objective Response Rate (ORR)

    Time frame: Up to 1.5 years

  4. Part 2, Arms 2-4: Number of Participants with DLTs

    Time frame: DLTs are assessed during the first cycle (28 days) in arms 2-4

  5. Part 2, Arms 2-5: Number of Participants with TEAEs

    Time frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years

Secondary outcomes

  1. Both parts: Area-under-the-concentration-time curve from Time 0 to Time of last dose (AUClast)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  2. Both parts: AUC from Time 0 to Infinity (AUCinf)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  3. Both parts: Maximum (Peak) Plasma Concentration (Cmax)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  4. Both parts: Time to Reach Cmax (Tmax)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  5. Both parts: Pre-dose (Trough) Concentrations (Cthrough)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  6. Both parts: Total Body Clearance of Drug from the Plasma (CL)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  7. Both parts: Volume of Distribution (Vd)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  8. Both parts: Elimination Half-life (t 1/2)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  9. Both parts: Number of Participants with Anti-Drug-Antibodies (ADAs)

    Time frame: From first dose until treatment discontinuation, expected average of 1 year

  10. Part 2, Arm 1: Number of Participants with TEAEs

    Time frame: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years

  11. Part 1 and Part 2, Arms 2-5: ORR

    Time frame: Up to 1.5 years

  12. Both parts: CR Rate

    Time frame: Up to 1.5 years

  13. Both parts: Duration of Response (DOR)

    Time frame: Up to 1.5 years

  14. Both parts: Progression Free Survival (PFS)

    Time frame: Up to 1.5 years

  15. Part 2: Duration of CR (DoCR)

    Time frame: Up to 1.5 years

  16. Part 2: Time to Response (TTR)

    Time frame: Up to 1.5 years

  17. Part 1 and Part 2 arm 1: Time to Next Anti-lymphoma Therapy (TTNT)

    Time frame: Up to 1.5 years

  18. Both parts: Overall Survival (OS)

    Time frame: Up to 1.5 years

07

Study locations

15 sites
08

References and documents

Publications

  • Sinnollareddy M, Sanghavi K, Gibiansky L, Li T, Putnins M, Mohamed MF, Patah P, Favaro E, Gupta M, Parikh A, Xu S. Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma. Clin Pharmacokinet. 2026 Aug 1. doi: 10.1007/s40262-026-01661-1. Online ahead of print. PubMed 42541678 ↗
  • Li T, Tredennick A, Polhamus D, Putnins M, Liu S, Sanghavi K, Thalhauser CJ, Parikh A, Noorani B, Mohamed MF, Le Gallo C, Elliott B, Gupta M, Xu S. Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation. Clin Pharmacol Ther. 2026 Aug;120(2):542-551. doi: 10.1002/cpt.70362. Epub 2026 Jul 7. PubMed 42411504 ↗
  • Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Conlon R, Takahashi A, D'Angelo Mansson B, Favaro E, Fukuhara N. Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. Leuk Lymphoma. 2025 Oct;66(10):1913-1921. doi: 10.1080/10428194.2025.2525983. Epub 2025 Jul 9. PubMed 40632620 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Sep 2027, 85 months after the start.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's planned 85 months is above that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Sep 9, 2020
StartActual
Aug 20, 2020
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04542824
Lead sponsor
Genmab
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Aug 20, 2020
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epcoritamab

Start the discussion